Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.
about
Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosisA balancing act: efflux/influx in mycobacterial drug resistanceSystematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolatesA Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-AnalysisRapid colorimetric testing for pyrazinamide susceptibility of M. tuberculosis by a PCR-based in-vitro synthesized pyrazinamidase methodAssociation between Mycobacterium tuberculosis complex phylogenetic lineage and acquired drug resistanceEpidemiology and Clinical Characteristics of Pediatric Drug-Resistant Tuberculosis in Chongqing, ChinaMechanisms of Pyrazinamide Action and ResistanceReevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.New strategies for antibacterial drug design: targeting non-multiplying latent bacteria.Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamideSurveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand.Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosisMycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter studyUncoupling Environmental pH and Intrabacterial Acidification from Pyrazinamide Susceptibility in Mycobacterium tuberculosisDose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosisPhenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Zhejiang, ChinaClinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases.Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variabilityReview: multidrug-resistant tuberculosis: public health challenges.Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosisComparative evaluation of Löwenstein-Jensen proportion method, BacT/ALERT 3D system, and enzymatic pyrazinamidase assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosisHost-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives.Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.The effect of growth rate on pyrazinamide activity in Mycobacterium tuberculosis - insights for early bactericidal activity?Epidemiologic Correlates of Pyrazinamide-Resistant Mycobacterium tuberculosis in New York City.Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT.Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis.Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of CaseumA Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in BabiesBedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice.Pyrazinamide Is Active against Mycobacterium tuberculosis Cultures at Neutral pH and Low Temperature.Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.Sputum PCR-single-strand conformational polymorphism test for same-day detection of pyrazinamide resistance in tuberculosis patients.New approach for drug susceptibility testing: monitoring the stress response of mycobacteria.Rapid detection of Mycobacterium tuberculosis and pyrazinamide susceptibility related to pncA mutations in sputum specimens through an integrated gene-to-protein function approachEnergy metabolism and drug efflux in Mycobacterium tuberculosis
P2860
Q24609567-19F1E9BC-8751-44F6-9F5A-B5C1C02BAA81Q24644870-C1F6A96A-C469-473D-916B-542346D9BE06Q27004697-977F83CF-309D-4604-AF6F-5E2BA7A61895Q27011264-CE3DBCAD-77CE-4F4A-8F73-25548F95D1B4Q28477917-42EEE2D0-285D-4365-B7A2-9D1DA79D4FB1Q28537951-FC057140-E15A-48FC-9EC0-854ED10E5B03Q28550637-8E9577A9-B7E5-41A6-9274-655D72AF54E9Q29304444-C8433734-9DAC-469F-B373-D9A8C7290CC1Q30224832-1DCF100B-389A-4C30-B208-7E480FABC00FQ33245712-0DBBA8B2-111C-4961-AEA5-BA5D888A408BQ33614112-CFA85C4C-C085-4D4C-ACFD-6EEBED67DEE4Q33667486-2CC41160-6106-4E10-8D0A-C0C926DF06C2Q33704769-72170ECD-6438-427F-933C-2A32ED0BD7FBQ34113610-E9A80D20-9C6C-4F33-8E20-30B0493E8BFAQ34420149-FE8686A4-2541-4F1F-AF45-CBC02C6BE3D2Q34494098-B3C27F32-D62A-4728-8B1A-8B12F61AA03BQ34737913-D28008D7-8E30-4C30-9D45-7A582DDEA51CQ34757821-39E6F887-96C7-4E2C-8367-CA2464CEEA73Q35076847-33C7B64C-3530-4179-BF99-DCB195F96F47Q35455573-D4578504-3949-4ABD-B8B3-44142562C7F2Q35532853-30F53480-95BC-4DBB-9647-5AB0A699F1CDQ35631580-83C20BE7-8DC3-4958-9BC8-B1CCC4DB89A4Q35687128-C08D937E-E7DF-4692-B7E3-D592DC351DA7Q35690257-A4DB1896-8B09-472C-85FC-2FF3BFDE2E89Q35743972-C67BFEEF-D39C-402F-B06C-D4B2C70356B7Q35879089-BD7299DA-4FE0-4B1B-99F2-AFD7AF8093C7Q36019139-FC59353A-EA09-4B39-8D26-0B067506F8D4Q36076037-4BF659AB-4F5D-41E2-87B5-23CF85A3A302Q36082638-640BAD9F-DF37-4969-9A92-1A969213ED51Q36174022-0B778C2E-475C-4330-92DF-5E57670CF704Q36540893-CDE02968-9E92-4610-8680-B4E17D3DC3C6Q36571981-ACEDD6D7-CC2B-4A26-86D5-7DF60ACCC65BQ36869913-914716BC-C03D-4546-956B-64017B811A63Q36921509-9359E4D8-C2BC-4F8D-A60E-A405CB30EC82Q37120038-D4CCF700-F842-4454-9321-628EA6BCC37CQ37274688-7A113C9E-58B2-4CA9-BD29-B2F17CFE3890Q37333692-EC6C5D74-41DD-4351-8894-F1DF75C84028Q37409911-24216E11-2617-4B57-86BE-73C4F99BB7A6Q37546819-87D6F1AE-15C9-4AA6-9622-CCBF48AE975DQ37712986-814EBE75-9EF6-4230-B953-919B3AF48D18
P2860
Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Conditions that may affect the ...... tuberculosis to pyrazinamide.
@ast
Conditions that may affect the ...... tuberculosis to pyrazinamide.
@en
Conditions that may affect the ...... tuberculosis to pyrazinamide.
@nl
type
label
Conditions that may affect the ...... tuberculosis to pyrazinamide.
@ast
Conditions that may affect the ...... tuberculosis to pyrazinamide.
@en
Conditions that may affect the ...... tuberculosis to pyrazinamide.
@nl
prefLabel
Conditions that may affect the ...... tuberculosis to pyrazinamide.
@ast
Conditions that may affect the ...... tuberculosis to pyrazinamide.
@en
Conditions that may affect the ...... tuberculosis to pyrazinamide.
@nl
P2093
P1476
Conditions that may affect the ...... tuberculosis to pyrazinamide.
@en
P2093
Sallie Permar
Ying Zhang
Zhonghe Sun
P356
10.1099/0022-1317-51-1-42
P577
2002-01-01T00:00:00Z